Antibiotic Resistance — The Slow Catastrophe Nobody Is Treating as One

In 2019, antimicrobial resistance directly caused 1.27 million deaths worldwide. It contributed to another 4.95 million. That makes it comparable to HIV/AIDS and tuberculosis as a cause of death — but unlike those diseases, antibiotic resistance doesn't have a recognizable face, doesn't generate telethons, and doesn't have a social movement demanding action. It's a slow catastrophe, which is exactly the kind of problem that modern institutions handle worst.

The basic mechanism is evolution. Bacteria reproduce fast — E. coli divides every 20 minutes under ideal conditions. In a large population of bacteria, random mutations constantly produce variants. Most mutations are neutral or harmful. But when antibiotics are present, a variant that happens to resist the antibiotic survives while others die. That resistant variant multiplies. Natural selection in real time, happening in your gut right now.

The resistance mechanisms bacteria evolve are genuinely clever. Some produce enzymes that chemically inactivate antibiotics — beta-lactamases destroy penicillin and related drugs; carbapenemases can destroy carbapenems, the last-resort drugs. Some bacteria modify the cell structures that antibiotics target, so the drug no longer binds. Some develop efflux pumps that actively eject antibiotics before they can act. And bacteria can share resistance genes horizontally — not just parent to offspring but between completely different bacterial species, through plasmids. A resistance gene that evolved in one species can spread to another within years.

The drug discovery pipeline has been effectively empty for decades. Most antibiotic classes in clinical use were discovered in the 1940s-1970s. Since then, essentially all "new" antibiotics have been modifications of existing classes — same targets, same mechanisms, same susceptibility to resistance. There are biological reasons: bacteria have evolved defenses against most small molecules that can penetrate their cell walls, limiting the chemical space to explore. There are also economic reasons: antibiotics are prescribed for short courses and patients recover — that's not a profitable business model compared to drugs for chronic conditions.

The geography of the problem is uneven. High-income countries over-prescribe antibiotics to humans. Low- and middle-income countries over-use them in agriculture — livestock are often given antibiotics continuously for growth promotion, a practice still legal in much of the world. India manufactures a significant fraction of the world's antibiotics and has severe resistance problems partly because pharmaceutical manufacturing effluent contaminating local waterways selects for resistance constantly. Resistance genes circulate globally through travel and trade.

Carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) are the most recognized problems in hospitals. But the most alarming trend is the spread of resistance in community-acquired infections — people getting resistant bacteria outside hospital settings, from food, water, or other people.

The solutions are understood but not implemented. Stewardship programs that restrict unnecessary antibiotic use work, where they're implemented. Agricultural reform to eliminate growth-promotion use would help. New business models for antibiotic development — subscription payments, delinked incentives — have been proposed and partially piloted but not adopted at scale. Phage therapy (using viruses that kill bacteria) has shown promise in case studies but hasn't been validated in large trials.

The tragedy of antibiotic resistance is that unlike most catastrophic risks, we know exactly what's happening, we know it will get worse, and the fixes are politically feasible. They're just not happening at the required speed.

Antibiotic Resistance — The Slow Catastrophe Nobody Is Treating as One

// COMMENTS

ON THIS PAGE